Drug Information

Drug General Information
Drug ID
D0I0UI
Former ID
DIB020613
Drug Name
ONO-AE2-227
Drug Type
Small molecular drug
Indication Discovery agent Investigative [541143]
Formula
C27H23NO3
InChI
InChI=1S/C27H23NO3/c1-18(22-15-8-12-19-9-2-5-13-23(19)22)26(29)28-25-16-7-4-11-21(25)17-20-10-3-6-14-24(20)27(30)31/h2-16,18H,17H2,1H3,(H,28,29)(H,30,31)
InChIKey
BLJLWFKNTKAUDA-UHFFFAOYSA-N
PubChem Compound ID
5311232
PubChem Substance ID
7979739, 11056363, 14830995, 39340940, 51669177, 103924802, 114155619, 143053879, 178102449, 231189601, 242633979, 242851728
Target and Pathway
Target(s) Prostaglandin E2 receptor EP3 subtype Target Info Antagonist [526239]
Prostaglandin E2 receptor, EP4 subtype Target Info Antagonist [526239]
KEGG Pathway Calcium signaling pathway
cAMP signaling pathway
Neuroactive ligand-receptor interaction
Regulation of lipolysis in adipocytes
Pathways in cancerhsa04080:Neuroactive ligand-receptor interaction
Inflammatory mediator regulation of TRP channels
Renin secretion
Pathways in cancer
NetPath Pathway IL2 Signaling PathwayNetPath_25:FSH Signaling Pathway
IL2 Signaling Pathway
IL4 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
Reactome Prostanoid ligand receptors
G alpha (i) signalling eventsR-HSA-391908:Prostanoid ligand receptors
G alpha (s) signalling events
WikiPathways Prostaglandin Synthesis and Regulation
GPCRs, Class A Rhodopsin-like
Small Ligand GPCRs
GPCR ligand binding
GPCR downstream signalingWP98:Prostaglandin Synthesis and Regulation
Vitamin D Receptor Pathway
GPCR downstream signaling
References
Ref 541143(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5824).
Ref 526239Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res. 2002 Jan 1;62(1):28-32.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.